SynthesisMedicine2018
Altered long noncoding RNAs and survival outcomes in ovarian cancer: A systematic review and meta-analysis (PRISMA Compliant).
Synthesis in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Prognostic Role of Long Noncoding RNAs in Oral Squamous Cell Carcinoma: A Meta-Analysis.Disease markers · 2021Pooled it
- Long non-coding RNA involved in the carcinogenesis of human female cancer - a comprehensive review.Discover oncology · 2025Review
- Article
- Exosomes: A potential tool for immunotherapy of ovarian cancer.Frontiers in immunology · 2022Review
- The impact of LncRNA dysregulation on clinicopathology and survival of pancreatic cancer: a systematic review and meta-analysis (PRISMA compliant).Cancer cell international · 2021Review
- Noncoding RNA (ncRNA) Profile Association with Patient Outcome in Epithelial Ovarian Cancer Cases.Reproductive sciences (Thousand Oaks, Calif.) · 2021Article
- Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum.RNA biology · 2020Review
- Review
- The Biological and Clinical Role of the Long Non-Coding RNA LOC642852 in Ovarian Carcinoma.International journal of molecular sciences · 2020Article
- Knockdown of long non-coding RNA LINC00176 suppresses ovarian cancer progression by BCL3-mediated down-regulation of ceruloplasmin.Journal of cellular and molecular medicine · 2020Article
- Noncoding RNAs in Extracellular Fluids as Cancer Biomarkers: The New Frontier of Liquid Biopsies.Cancers · 2019Review
- Long Non-coding RNAs Involved in Resistance to Chemotherapy in Ovarian Cancer.Frontiers in oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies investigating the association between altered long noncoding RNAs (lncRNAs) and survival outcomes in ovarian cancer have obtained controversial results. To comprehensively evaluate the association, we conducted a systematic review and meta-analysis of the studies published on the subject.
methodsWe performed a systematic search using the databases of the Cochrane Central Register of Controlled Trials, PubMed, and Embase to find all relevant articles from inception to May 7, 2017. Studies that evaluated the association between 1 specific lncRNA and survival outcomes in ovarian cancer were included. Pooled hazard ratios (HRs) and 95% confidence intervals (95% CIs) for overall survival, progression-free survival, and disease-free survival were calculated with a fixed-effects or random-effects model.
resultsA total of 15 studies involving 1333 patients with ovarian cancer were included in this meta-analysis. Altered lncRNAs were associated with decreased overall survival (HR: 2.29, 95% CI: 1.92-2.75) without heterogeneity (I = 0.0%) in ovarian cancer. Altered lncRNAs were also associated with decreased progression-free survival (HR: 2.77, 95% CI: 1.00-7.62, I = 76.6%) and disease-free survival (HR: 2.59, 95% CI: 0.89-7.57, I = 62.9%) in ovarian cancer.
conclusionOur results supported the strong prognostic value of altered lncRNAs in ovarian cancer. Further large-scale studies should be carried out to verify the clinical applications of altered lncRNAs in the prognosis assessment of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.